Dr. Marcus A. Conant is a dermatologist and HIV/AIDS specialist practicing in the Castro neighborhood of San Francisco.
We are currently only accepting new patients for cosmetic dermatology procedures, which includes Sculptra, or dermatology consultations on a referral basis from your primary care physician.
FDA approves injectable poly-L-lactic acid to correct nasolabial fold contour deficiencies.
Medscape (7/30, Waknine) reported that the Food and Drug Administration “has approved injectable poly-L-lactic acid (Sculptra Aesthetic, Sanofi-Aventis US) for use in immune-competent people to correct shallow to deep nasolabial fold contour deficiencies (’smile wrinkles’) and other facial wrinkles in which” the “deep dermal grid pattern (cross-hatch) injection technique is appropriate.” The FDA granted approval based “on data from a randomized, comparative, evaluator-blinded, parallel-group, multicenter study (n = 233) showing that use of the product yielded greater improvements in wrinkle correction at 13 months compared with human-derived collagen, as determined by wrinkle assessment scores.” The substance “is administered as a single treatment regimen of up to four sessions at three-week intervals,” and “should not be used in patients with hypersensitivity to product components or in those with known history of or susceptibility to keloid formation or hypertrophic scarring.”
In order to qualify for the Sculptra Patient Access Program, you will need to do the following:
You may fax the information to 415-575-7503,
or you may mail to:
4053 18th Street
San Francisco, Ca 94114
If you have questions, please feel free to contact us at 415-575-7500.
Please note: Sculptra and other cosmetic procedures are performed at the above 18th street address.
Facial Lipodystrophy
Facial lipodystrophy syndrome (FLS) (sometimes called facial lipoatrophy), is characterized by lost volume, resulting in a marked hollowing of the face, causing sunken cheeks, bitemporal wasting, oral commissures, and deep nasolabial folds.
Sculptra® is approved by the FDA for restoration and/or correction of the signs of FLS in people with human immunodeficiency virus.